On 10 February, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015. On Wednesday shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) closed at $3.25.
On 9 February, QUALCOMM, Inc. (NASDAQ:QCOM) said that it has agreed to pay China a fine of $975 million, the largest in the country’s corporate history, ending a 14-month government investigation into anti-competitive practices. QUALCOMM, Inc. (NASDAQ:QCOM) in last trading activity increased 0.38% to close at $70.53. Company weekly performance is 5.32% while its quarterly performance stands at 2.27%. QUALCOMM, Inc. (NASDAQ:QCOM) is -12.98% away from its 52 week high.
Banco Bradesco S.A. (NYSE:BBD) announced a cash dividend. Payment of $0.052837 per share Shareholders who purchased BBDO stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 633.44% increase over the prior month. On last trading day Banco Bradesco S.A. (NYSE:BBD) moved down -3.76% to close at $12.04. Its volatility for the week is 2.47% while volatility for the month is 3.05%. BBD’s sales growth for past 5 years was 11.00% and its EPS growth for past 5 years was 12.40%. Banco Bradesco S.A. (NYSE:BBD) monthly performance is -7.67%.
Cintas Corporation (NASDAQ:CTAS) has earned an “A” credit rating from analysts at Morningstar. The investment research firm’s “A” rating suggests that the company is a low default risk. They also gave their stock a one star rating. Cintas Corporation (NASDAQ:CTAS) has 9.20% insider ownership while its institutional ownership stands at 72.20%. In last trading activity company’s stock closed at $80.94.
On 10 February, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted a quarterly net profit of $110.2 million, or $0.96 per share, versus a year-ago profit of $96.8 million, or $0.86 per share, in the year-ago period. Excluding special items, the company earned $2.79 per share. On last trading day Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) moved down -0.43% to close at $398.99. Its volatility for the week is 2.74% while volatility for the month is 3.18%. REGN’s sales growth for past 5 years was 54.60% and its EPS growth for past 5 years was 42.20%. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) monthly performance is -3.47%.